The author reflects on a proposal to extend the law informally known as the Physician Payments Sunshine Act (PPSA) to include payments to patient advocacy groups (PAG). She comments on the role of the U.S. Centers for Medicare and Medicaid Services (CMS) in monitoring payments by pharmaceutical companies to physicians and states an expansion of the PPSA would need to be justified based on their effect on CMS drug expenditures. She talks about how PAG could qualify under PPSA disclosure rules.
© 2001-2026 Fundación Dialnet · Todos los derechos reservados